Concomitant oral anti-diabetic drugs (OADs) were allowed for all trials (except in SUSTAIN 1, which was a monotherapy trial)
Thyroid C-cell risk has been observed in rodent studies, where GLP-1 receptor agonists led to C-cell tumor development
We solve that by offering: We work directly with trusted manufacturers, including Hospira (Pfizer), to avoid the repackaged or mislabeled reconstitution solutions commonly found on Amazon
However, secondary preventative interventions such as antiplatelet drugs, -blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARBs), and HMG-CoA reductase inhibitors (statins) have been shown to significantly reduce CVD risk [3]
The key difference lies in regulatory pathway, not therapeutic mechanism